Post Profile






Gilead's new drug keeps 56 percent of lymphoma trial patients alive

(Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.
read more

share

Related Posts


Gilead's HIV drug meets goal in four late-stage studies

Health : Reuters: Health

(Reuters) - Gilead Sciences Inc said on Tuesday a combination of its experimental HIV drug with existing therapies met the main goal in four late-stage studies.

FDA approves Gilead's drug for chronic hep C patients

Health : Reuters: Health

(Reuters) - Gilead Sciences Inc said on Tuesday that the U.S. Food and Drug Administration approved its hepatitis C drug for patients who had failed to respond to prior treatments.

Gilead cancer immunotherapy wins U.S. approval with $373,000 price

Health : Reuters: Health

(Reuters) - A new therapy for a type of lymphoma developed by Kite Pharma, which was acquired by Gilead Sciences Inc, won U.S. approval on Wednesday, marking the second approval for this potentially revolutionary approach to fightin...

U.S. FDA approves Gilead cancer gene therapy; price set at $373,000

Health : Reuters: Health

(Reuters) - U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting can...

FDA approves Gilead's Yescarta cancer immunotherapy

Health : Reuters: Health

(Reuters) - A new cancer therapy for a type of lymphoma developed by Kite Pharma, which was recently acquired by Gilead Sciences Inc, won U.S. Food and Drug Administration approval on Wednesday, six weeks ahead of schedule.

Comments


Copyright © 2016 Regator, LLC